Advertisement

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis

      Among patients with psoriasis who did not achieve Psoriasis Area and Severity Index 50 during the first course of alefacept therapy, 53% achieved Psoriasis Area and Severity Index 50 during the second course (odds ratio [95% confidence interval] vs placebo 2.30 [1.26-4.19]). Alefacept provided incremental efficacy over 5 successive 12-week treatment courses.

      Abbreviations used:

      IM (intramuscular), IV (intravenous), PASI (Psoriasis Area and Severity Index), PGA (Physician Global Assessment)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Krueger G.G.
        • Papp K.A.
        • Stough D.B.
        • Loven K.H.
        • Gulliver W.P.
        • Ellis C.N.
        • for the Alefacept Clinical Study Group
        A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis.
        J Am Acad Dermatol. 2002; 47: 821-833
        • Lebwohl M.
        • Christophers N.
        • Langley R.
        • Ortonne J.P.
        • Roberts J.
        • Griffiths C.E.
        • for the Alefacept Clinical Study Group
        An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
        Arch Dermatol. 2003; 139: 719-727
        • Gordon K.B.
        • Langley R.G.
        Remittive effects of intramuscular alefacept in psoriasis.
        J Drugs Dermatol. 2003; 2: 624-628
        • Carlin C.S.
        • Feldman S.R.
        • Krueger J.G.
        • Menter A.
        • Krueger G.G.
        A 50% reduction in the Psoriasis Area and Severity Index (PASI) is a clinically significant endpoint in the assessment of psoriasis.
        J Am Acad Dermatol. 2004; 50: 859-866
        • Ellis C.N.
        • Mordin M.M.
        • Adler E.Y.
        Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial.
        Am J Clin Dermatol. 2003; 4: 131-139
        • Finlay A.Y.
        • Salek M.S.
        • Haney J.
        • for the Alefacept Clinical Study Group
        Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis.
        Dermatology. 2003; 206: 307-315
        • Feldman S.R.
        • Menter A.
        • Koo J.Y.
        Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis.
        Br J Dermatol. 2004; 150: 317-326
        • Lowe N.J.
        • Gonzalez J.
        • Bagel J.
        • Caro I.
        • Ellis C.N.
        • Menter A.
        Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy.
        Int J Dermatol. 2003; 42: 224-230
      1. Menter A, Cather JC. Long-term use of alefacept: safety and off-treatment responses in patients who have received multiple courses of therapy. Poster presented at: 62nd Annual Meeting of the American Academy of Dermatology; February 6-11, 2004; Washington, DC.

        • Ellis C.N.
        • Krueger G.G.
        • for the Alefacept Clinical Study Group
        Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.
        N Engl J Med. 2001; 345: 248-255